The European Union Intellectual Property Office (EUIPO) has announced the opening of a new fund for 2026, enabling SMEs established in one of the 27 EU Member States...

Hermione Thompson and John Leeming are partners and European and UK Patent Attorneys at J A Kemp.

On 23 March 2023, the Genetic Technology (Precision Breeding) Act passed into law in England, allowing use of gene-edited crops and livestock in English agriculture for the first time.

On 11 June 2019, the EU published Regulation (EU) 2019/933, which amends Regulation (EC) 469/2009 concerning supplementary protection certificates (SPCs).

The UK Government has given assurances to holders of EU intellectual property rights that after Brexit those rights will remain protected in the UK.

Commentators have been concerned that implementation of the Unitary Patent (UP), which is intended to be a single patent right having effect in the territory of participating EU members...

The EPO has announced today that all opposition division oral proceedings scheduled to take place in 2020 are being postponed.

On 24 September 2018 the UK Government published a series of Technical Notices addressing various scenarios in which the UK leaves the European Union without an agreement, the so-called "no deal" or "hard" Brexit scenario.

On 24 September 2018 the UK Government published a series of Technical Notices addressing various scenarios in which the UK leaves the European Union without an agreement, the so-called "no deal" or "hard" Brexit scenario.

We recently reported that the EPO's Enlarged Board of Appeal has scheduled a hearing date of 28 May 2021 for the referral regarding the legality of video conference oral proceedings without the consent of one or more of the parties.

Increasing numbers of patent applications directed to microorganisms and specific strain(s) are being filed and granted. In this webinar, we will discuss how a physical biological deposit is made...

J A Kemp and DLRC explore intellectual property challenges arising from the EU Clinical Trials Regulation's transparency requirements. Presenters Karen Ng and James Biddlecombe emphasize strategic patent filing, early engagement, and collaboration between legal and regulatory teams to enhance patent opportunities in clinical trials.

The recent Enlarged Board of Appeal decisions G1/22 and G2/22 on priority entitlement provide a good opportunity to review this complex issue.

This webinar explores the complex landscape of patent applications for microorganisms and specific strains, examining when biological deposits are necessary and how they impact patent strategy. Attendees will learn practical approaches to drafting applications that support both deposited strain claims and broader microorganism claims, while understanding the scope of protection and potential infringement scenarios.

This webinar examines how the Enlarged Board of Appeal decision G1/19 and the UK Supreme Court's Emotional Perception judgment have reshaped patent examination practices at the EPO and UK IPO, with particular focus on recent appeal decisions and their implications for computer-implemented inventions. The session explores how these landmark rulings have intensified scrutiny of technical character requirements across claim scope and aligned UK practice more closely with EPO standards.

The Board of Appeal in T 697/22 has referred questions to the Enlarged Board of Appeal (EBA) concerning whether the description should be amended to address any inconsistencies with the claims.

In our earlier news item concerning G2/24, we reported that the Board of Appeal in T1286/23 had referred the following questions to the EPO's Enlarged Board of Appeal regarding the status...

Added matter remains one of the most challenging and unforgiving aspects of European prosecution and post-grant actions.

The Board of Appeal in T697/22 referred questions to the Enlarged Board of Appeal regarding whether the description should be amended to address any inconsistencies with the claims.

The Paris Local Division of the Unified Patent Court has clarified the standard for implicit novelty in patent disputes, aligning its approach with established EPO practice by requiring that unstated features follow 'inevitably and without any reasonable doubt' from prior art. In SharkNinja v SEB, the Court refused provisional measures after finding a cooking appliance patent more likely invalid than valid, applying a novelty test that closely mirrors European Patent Office guidelines...